Quest Diagnostics Incorporated
Clinical Laboratory Services / Diagnostic Information ServicesFounded 1967- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Quest Diagnostics Incorporated
Company History
Founded 1967 in Secaucus, New Jersey, United States
Last reviewed: 2025-07-15 · By Swet Parvadiya
The company added an 85-biomarker Elite Health Profile to its consumer offerings and launched an AI Companion tool that has been engaged approximately 350,000 times since rollout. Quest Diagnostics Incorporated is the world's leading provider of diagnostic information services, founded in 1967 as Metropolitan Pathology Laboratory by Dr. Paul A. Brown in Teaneck, New Jersey. Specimens are transported via a dedicated fleet of ground vehicles and aircraft — including the LabQuest airline operation originally acquired with SmithKline Beecham Clinical Laboratories — to regional and national laboratories for analysis using automated chemistry analyzers, immunoassay systems, molecular diagnostic platforms, next-generation sequencing instruments, and digital pathology systems. Quest Diagnostics traces its origins to a small pathology laboratory founded in 1967 by Dr. Paul A. Brown in Teaneck, New Jersey.
Kenneth W. Freeman was appointed CEO of the newly independent entity, which began trading on the New York Stock Exchange under ticker DGX. In November 2018, Quest launched QuestDirect, its consumer-initiated testing service. Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. In 2025, Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients.
Dr. Paul A. Brown was the founder of Metropolitan Pathology Laboratory, Inc. in 1967, the predecessor company to Quest Diagnostics. A practicing pathologist, Brown established the laboratory in Teaneck, New Jersey, to provide clinical pathology and anatomic pathology services to physicians and hospitals in the region. In 1969, the company was renamed MetPath, Inc. Brown led the company's early growth through clinical excellence and physician relationships before Corning Glass Works acquired MetPath in 1982. Brown's founding established the clinical culture and quality focus that would define Quest Diagnostics throughout its evolution from a small regional lab to a global diagnostic enterprise.
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory, Inc. in Teaneck, New Jersey, to provide clinical laboratory services to local physicians and hospitals. The company was renamed MetPath, Inc. in 1969.
Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. This acquisition provided capital and corporate infrastructure for expansion but also meant the laboratory business was a small division within a larger materials science company.
On December 31, 1996, Quest Diagnostics became an independent company through a spin-off from Corning and began trading on the NYSE under ticker DGX. Kenneth W. Freeman was appointed CEO. The spin-off provided strategic flexibility to pursue an acquisition-driven growth strategy.
Quest acquired SmithKline Beecham Clinical Laboratories for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in 1998 revenue and added a national network of laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size and established it as the industry leader.
Quest acquired Unilab Corporation for $800 million, significantly expanding its West Coast presence and adding substantial volume in California and surrounding states. The acquisition required divestiture of certain Northern California assets to LabCorp for antitrust clearance.
Quest acquired LabOne, Inc. for $934 million, adding employer drug testing and paramedical testing capabilities that expanded the company's service offerings beyond traditional clinical laboratory testing.
Quest acquired AmeriPath and its subsidiary Specialty Laboratories for approximately $1.23 billion, adding anatomic pathology and cancer diagnostic testing capabilities that complemented Quest's clinical chemistry strengths.
Quest acquired Athena Diagnostics (neurodegenerative disease testing) and Celera Corporation (genomics and sequencing), adding advanced diagnostics capabilities in neurology and genetic testing that would become foundational for future growth initiatives.
Quest acquired Solstas Lab Partners Group for $570 million, expanding its geographic footprint in the Southeastern United States and adding hospital outreach laboratory relationships.
Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing without a physician order in states where permitted. This marked Quest's entry into the direct-to-consumer diagnostic market.
Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. The pandemic created both operational challenges and substantial revenue opportunities for the company.
Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases and expanding Quest's international genomics expertise.
Jim Davis succeeded Steve Rusckowski as CEO on November 1, 2022, after serving as Executive Vice President of General Diagnostics. Davis brought experience from GE Healthcare, InSightec, and McKinsey & Company. He became Chairman on April 1, 2023.
Quest acquired Haystack Oncology, a minimal residual disease testing company, and the outreach laboratory operations of NewYork-Presbyterian Hospital for $275 million, expanding advanced oncology diagnostics and health system partnerships.
Quest completed the acquisition of LifeLabs from OMERS for approximately CAD $1.35 billion (USD ~$1 billion), adding Canada's leading laboratory diagnostic provider with 6,500+ employees, 8+ million online portal users, and approximately CAD $970 million in annual revenue. LifeLabs continues to operate under its own brand.
Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients annually in the United States.
Quest reported record 2025 results with $11.035 billion in revenue (up 11.8%), operating income of $1.556 billion (up 15.6%), and cash from operations of $1.886 billion (up 41.4%). The company raised 2026 guidance and increased its quarterly dividend 7.5% to $0.86 per share.
Quest acquired SBCL to become the clear industry leader in diagnostic testing. SBCL added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size.
Quest acquired Unilab to significantly expand its West Coast presence, particularly in California. Unilab was a major regional laboratory operator with strong market positions on the West Coast.
Quest acquired AmeriPath to add anatomic pathology and cancer diagnostic testing capabilities. AmeriPath was a leading provider of anatomic pathology, dermatopathology, and molecular diagnostics.
Quest acquired Solstas to expand its geographic footprint in the Southeastern United States and add hospital outreach laboratory relationships in that region.
Quest acquired Blueprint Genetics (Helsinki, Finland) to add genetic testing capabilities for rare diseases and hereditary conditions, expanding Quest's genomics and precision medicine portfolio.
Quest acquired Haystack Oncology, a minimal residual disease (MRD) testing company, to enter the emerging MRD testing market for solid tumors. MRD testing monitors cancer recurrence by detecting circulating tumor DNA.
Quest acquired LifeLabs from OMERS to establish a dominant position in Canadian laboratory services and expand internationally. LifeLabs is Canada's leading lab provider with 6,500+ employees and 8+ million online portal users.
Quest acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories to expand renal-specific testing capabilities for dialysis patients.
Quest Diagnostics traces its origins to 1967, when Dr. Paul Brown founded Metropolitan Pathology Laboratory, known as MetPath, in Teaneck, New Jersey. Brown, a physician and entrepreneur, identified an opportunity to consolidate clinical pathology services that had historically been performed in fragmented hospital and physician-office laboratories. MetPath grew through the 1970s by signing reference-lab agreements with hospitals and physician practices that wanted to outsource specialty testing rather than build internal capability. By the early 1980s MetPath had become one of the larger US clinical laboratories, with a national logistics footprint to ship specimens overnight from outlying collection sites to centralized testing facilities. In 1982 the company was acquired by Corning Glass Works, the upstate New York industrial conglomerate, which had been diversifying into healthcare and life-sciences testing. MetPath operated as the clinical-laboratory arm of Corning's life-sciences business through the 1980s and early 1990s, expanding its national footprint through acquisitions. In 1996 Corning spun off the clinical-laboratory operations as a new independent public company called Quest Diagnostics Incorporated, distributing shares to Corning shareholders. The Quest Diagnostics ticker DGX began trading on the New York Stock Exchange in January 1997, marking the start of the modern company.
Corning Glass Works, which had acquired MetPath in 1982 and built out its life-sciences laboratory operations through the 1980s and early 1990s, announced in 1995 that it would spin off both Quest Diagnostics and the pharmaceutical-services subsidiary Covance as independent public companies. The spinoff completed at the end of 1996 with shares distributed to Corning shareholders, and Quest Diagnostics began trading independently on the New York Stock Exchange under ticker DGX in January 1997. The strategic rationale was that the clinical laboratory business required different operating models, capital allocation, and management focus than Corning's core specialty glass, ceramics, and fiber-optics businesses. Healthcare investors valued laboratory operations on different multiples than industrial conglomerates, suggesting that Quest could trade at a higher valuation as a pure-play laboratory company than as a Corning subsidiary. The spinoff also addressed regulatory and reimbursement concerns specific to the laboratory sector, particularly Medicare fraud investigations that had affected multiple labs in the early 1990s. As an independent company, Quest Diagnostics could focus management attention on healthcare-specific operational and regulatory issues. Within three years of the spinoff, Quest acquired SmithKline Beecham Clinical Laboratories for $1.3 billion and became the largest clinical laboratory company in the United States.
Quest Diagnostics announced in February 1999 that it would acquire SmithKline Beecham Clinical Laboratories from pharmaceutical company SmithKline Beecham, closing the cash-and-stock deal in August 1999 for approximately $1.3 billion. SmithKline Beecham Clinical Laboratories, known as SBCL, was the second-largest US clinical laboratory at the time, with annual revenue of roughly $1.6 billion, operating from a national network of testing facilities and patient service centers. By combining SBCL with the existing Quest network, the merged company became the largest clinical laboratory in the United States by revenue, ahead of LabCorp, which had until then been the leading commercial laboratory. The combined entity served physicians, hospitals, employers, and government payors across all 50 states. Quest absorbed SBCL operations over several years, consolidating overlapping testing facilities, integrating logistics, and migrating the SBCL physician relationships onto Quest billing and reporting systems. The acquisition was financed with a combination of new debt and equity issued to SmithKline Beecham, which retained a stake in Quest for a period before divesting. The deal transformed the clinical laboratory industry into the duopoly structure dominated by Quest Diagnostics and LabCorp that has defined the sector for the past quarter century.
Quest Diagnostics is headquartered at 500 Plaza Drive in Secaucus, New Jersey, in the New York metropolitan area, having relocated its corporate offices from Lyndhurst, New Jersey in the early 2000s. The company operates one of the largest clinical laboratory networks in the world, with more than 50,000 employees, approximately 2,000 patient service centers across the United States, and 14 major laboratory campuses that process approximately 1 million specimens per day. Quest provides more than 3,500 different diagnostic tests across general health, infectious disease, cardiovascular, oncology, genomics, women's health, and toxicology, plus specialized services in clinical trials testing, employer drug screening, and direct-to-consumer testing under the Quest Health brand. Roughly half of US adults will see a Quest result in their medical record over the course of a year, with annual revenue of approximately $11 billion in 2024. Customers include physicians, hospitals, health systems, employers, insurance plans, government payors including Medicare and Medicaid, pharmaceutical companies running clinical trials, and consumers paying directly. The company is publicly traded on the New York Stock Exchange under ticker DGX with a market capitalization of approximately $19 billion as of mid-2025.
Quest Diagnostics has executed a programmatic acquisition strategy aimed at consolidating regional and specialty laboratories into its national network. Notable deals include the 2003 acquisition of Unilab for approximately $1.05 billion, which gave Quest a stronger California presence; the 2011 acquisitions of Athena Diagnostics, Berkeley HeartLab, and Celera Genomics for $671 million combined, adding specialty neurology, cardiovascular risk, and molecular oncology testing; the 2023 acquisition of Haystack Oncology for approximately $300 million, which brought minimal residual disease testing for early cancer detection; the 2024 acquisition of LabCorp's Pacific Diagnostic Laboratories operations in California; and the 2024 acquisition of Cleveland Clinic's outreach laboratory business. Quest has also acquired multiple regional independent laboratories in 2024 and 2025, including Allina Health laboratory operations and PathAI Diagnostics' anatomic pathology assets. The acquisition cadence has been deliberately programmatic, with Quest typically targeting bolt-on deals in the $50 million to $500 million range that add geographic density, specialty testing capabilities, or hospital outreach relationships. Cumulative spending on M&A has exceeded $5 billion over the past decade, contributing meaningfully to revenue growth even in periods when same-store volumes and reimbursement rates have been pressured by Medicare cuts and insurer contracting.